{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02016924",
            "orgStudyIdInfo": {
                "id": "GS-US-216-0128"
            },
            "secondaryIdInfos": [
                {
                    "id": "2013-001402-28",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV",
            "officialTitle": "A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants",
            "therapeuticArea": [
                "Rare Diseases",
                "Infectious Diseases"
            ],
            "study": "study-of-cobicistat-boosted-atazanavir-atv-co-cobicistat-boosted-darunavir-drv-co-and-emtricitabine-tenofovir-alafenamide-f-taf-in-children-with-hiv"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2014-01-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2013-12-16",
            "studyFirstSubmitQcDate": "2013-12-16",
            "studyFirstPostDateStruct": {
                "date": "2013-12-20",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age \u2265 4 weeks to \\< 18 years) with HIV."
        },
        "conditionsModule": {
            "conditions": [
                "Acquired Immune Deficiency Syndrome (AIDS)",
                "HIV Infections"
            ],
            "keywords": [
                "Pediatrics",
                "Adolescents",
                "HIV",
                "HIV-1",
                "Treatment experienced"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Part A and Part B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants ages 12 to \\<18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: DRV",
                        "Drug: Cobicistat",
                        "Drug: BR"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants aged 6 to \\<12 years old and \u226525 to \\<40kg will receive cobicistat 150 mg and F/TAF 200/25 mg with either ATV or DRV.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: DRV",
                        "Drug: Cobicistat",
                        "Drug: F/TAF"
                    ]
                },
                {
                    "label": "Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants age \u2265 2 years old will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: DRV",
                        "Drug: Cobicistat",
                        "Drug: F/TAF"
                    ]
                },
                {
                    "label": "Cohort 4 (Group 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants age \u2265 4 weeks old weighing 14 to \\< 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is \u2265 3 months and \u2265 5 kg, minimum age and weight for DRV is \u2265 3 years and \u2265 15 kg; participants receiving LPV/r will not receive cobicistat TOS.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: DRV",
                        "Drug: LPV/r",
                        "Drug: Cobicistat TOS",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 4 (Group 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants age \u2265 4 weeks old weighing 10 to \\< 14 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 60/7.5 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is \u2265 3 months and \u2265 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: LPV/r",
                        "Drug: Cobicistat TOS",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 4 (Group 3)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants age \u2265 4 weeks old weighing 6 to \\< 10 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 30/3.75 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is \u2265 3 months and \u2265 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: LPV/r",
                        "Drug: Cobicistat TOS",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 4 (Group 4)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants age \u2265 4 weeks old weighing 3 to \\< 6 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 15/1.88 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is \u2265 3 months and \u2265 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.",
                    "interventionNames": [
                        "Drug: ATV",
                        "Drug: LPV/r",
                        "Drug: Cobicistat TOS",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 5 (Group 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants ages \u2265 4 weeks old weighing \u2265 10 to \\< 14 kg will receive F/TAF TOS 60/7.5 mg, once daily with the third unboosted drug.",
                    "interventionNames": [
                        "Drug: Third Unboosted Drug",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 5 (Group 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants ages \u2265 4 weeks old weighing \u2265 6 to \\< 10 kg will receive F/TAF TOS 30/3.75 mg, once daily with the third unboosted drug.",
                    "interventionNames": [
                        "Drug: Third Unboosted Drug",
                        "Drug: F/TAF TOS"
                    ]
                },
                {
                    "label": "Cohort 5 (Group 3)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants ages \u2265 4 weeks old weighing \u2265 3 to \\< 6 kg will receive F/TAF TOS 15/1.88 mg, once daily with the third unboosted drug.",
                    "interventionNames": [
                        "Drug: Third Unboosted Drug",
                        "Drug: F/TAF TOS"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ATV",
                    "description": "Capsules administered once daily according to dosing recommendations per product monograph",
                    "armGroupLabels": [
                        "Cohort 1: Part A and Part B",
                        "Cohort 2",
                        "Cohort 3",
                        "Cohort 4 (Group 1)",
                        "Cohort 4 (Group 2)",
                        "Cohort 4 (Group 3)",
                        "Cohort 4 (Group 4)"
                    ],
                    "otherNames": [
                        "Reyataz\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "DRV",
                    "description": "Tablets administered once daily according to dosing recommendations per product monograph",
                    "armGroupLabels": [
                        "Cohort 1: Part A and Part B",
                        "Cohort 2",
                        "Cohort 3",
                        "Cohort 4 (Group 1)"
                    ],
                    "otherNames": [
                        "Prezista\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cobicistat",
                    "description": "Tablets administered orally once daily with food",
                    "armGroupLabels": [
                        "Cohort 1: Part A and Part B",
                        "Cohort 2",
                        "Cohort 3"
                    ],
                    "otherNames": [
                        "GS-9350",
                        "Tybost\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BR",
                    "description": "Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).",
                    "armGroupLabels": [
                        "Cohort 1: Part A and Part B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "F/TAF",
                    "description": "Tablets administered orally once daily",
                    "armGroupLabels": [
                        "Cohort 2",
                        "Cohort 3"
                    ],
                    "otherNames": [
                        "Descovy\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LPV/r",
                    "description": "Solution administered orally",
                    "armGroupLabels": [
                        "Cohort 4 (Group 1)",
                        "Cohort 4 (Group 2)",
                        "Cohort 4 (Group 3)",
                        "Cohort 4 (Group 4)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Third Unboosted Drug",
                    "description": "ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.",
                    "armGroupLabels": [
                        "Cohort 5 (Group 1)",
                        "Cohort 5 (Group 2)",
                        "Cohort 5 (Group 3)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cobicistat TOS",
                    "description": "Tablets for oral suspension",
                    "armGroupLabels": [
                        "Cohort 4 (Group 1)",
                        "Cohort 4 (Group 2)",
                        "Cohort 4 (Group 3)",
                        "Cohort 4 (Group 4)"
                    ],
                    "otherNames": [
                        "GS-9350",
                        "Tybost\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "F/TAF TOS",
                    "description": "Tablets for oral suspension",
                    "armGroupLabels": [
                        "Cohort 4 (Group 1)",
                        "Cohort 4 (Group 2)",
                        "Cohort 4 (Group 3)",
                        "Cohort 4 (Group 4)",
                        "Cohort 5 (Group 1)",
                        "Cohort 5 (Group 2)",
                        "Cohort 5 (Group 3)"
                    ],
                    "otherNames": [
                        "Descovy\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV",
                    "description": "AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).\n\nAUCtau for ATV (Cohorts 1 Part A, 2, 3, and 4 \\[Groups 2 to 4\\]); DRV (Cohorts 1 Part A, 2, and 3); TAF (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 \\[Groups 1 to 3\\] taking F/TAF); and TFV (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 \\[Groups 1 to 3\\] taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) Through Week 24",
                    "timeFrame": "First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities Through Week 24",
                    "timeFrame": "First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK Parameter: Ctau of ATV, DRV, COBI, FTC and TFV",
                    "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval.\n\nCtau for ATV (cohorts 1, 2, 3, and 4 (Groups 2 to 4)), DRV (cohorts 1, 2, and 3), COBI (except Cohort 5), FTC and TFV (cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: Cmax of ATV, DRV, COBI, TAF, FTC and TFV",
                    "description": "Cmax is defined as the maximum observed concentration of drug.\n\nCmax for ATV (Cohorts 1, 2, 3, and 4 \\[Groups 2 to 4\\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: CL/F of ATV, DRV, COBI, TAF, FTC and TFV",
                    "description": "CL/F is defined as the apparent oral clearance following administration of the drug.\n\nCL/F for ATV (Cohorts 1, 2, 3, and 4 \\[Groups 2 to 4\\]) and DRV (Cohorts 1, 2, and 3); for COBI (except Cohort 5); for TAF, FTC and TFV (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: Vz/F of COBI, TAF, FTC and TFV",
                    "description": "Vz/F is defined as the apparent volume of distribution of the drug.\n\nVz/F for COBI (Except Cohort 5); for TAF (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: AUCtau of COBI and FTC",
                    "description": "AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).\n\nAUCtau for COBI (Except Cohort 5) and FTC will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: AUClast of TAF, FTC and TFV",
                    "description": "AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.\n\nAUClast for TAF (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF); for FTC and TFV (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "PK Parameter: Clast of TAF",
                    "description": "Clast is defined as the the last observed quantifiable concentration of the drug in plasma.\n\nClast for TAF (Cohorts 2, 3, 4 \\[Groups 1 to 4\\] and 5 taking F/TAF) will be reported.",
                    "timeFrame": "Predose on Day 1, and postdose up to Week 48"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)",
                    "timeFrame": "First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)"
                },
                {
                    "measure": "Percentage of Participants Experiencing Clinically Significant Changes in Safety Laboratory Values",
                    "timeFrame": "First dose date up to Week 48 plus 30 days (Cumulative data through Week 48)"
                },
                {
                    "measure": "Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 24 and as Defined by the US FDA-defined Snapshot Algorithm",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Percentage of Participants with HIV-1 RNA < 50 Copies/mL at Week 48 and as Defined by the US FDA-defined Snapshot Algorithm",
                    "timeFrame": "Week 48"
                },
                {
                    "measure": "Change from Baseline in CD4+ Cell Counts (cells/\u03bcL) at Week 24",
                    "timeFrame": "Baseline, Week 24"
                },
                {
                    "measure": "Change from Baseline in CD4+ Cell Counts (cells/\u03bcL) at Week 48",
                    "timeFrame": "Baseline, Week 48"
                },
                {
                    "measure": "Change from Baseline in Percentage of CD4+ Cells at Week 24",
                    "timeFrame": "Baseline, Week 24"
                },
                {
                    "measure": "Change from Baseline in Percentage of CD4+ Cells at Week 48",
                    "timeFrame": "Baseline, Week 48"
                },
                {
                    "measure": "Acceptability of COBI and F/TAF as Measured by Palatability Score",
                    "timeFrame": "Week 48"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* HIV-1 infected, virologically suppressed males and females age \u2265 4 weeks to \\< 18 years (according to requirements of enrolling Cohort).\n* Body weight at screening \u2265 25 to \\< 40 kg (Cohort 2); \u2265 14 to \\< 25 kg (Cohort 3); \u2265 3 to \\< 25 kg (Cohort 4); \u2265 3 to \\< 14 kg (Cohort 5).\n* Stable antiretroviral (ARV) regimen for a minimum of 3 months prior to the screening visit.\n\n  * Participants enrolled prior to implementation of Amendment 7: 2 nucleoside reverse transcriptase inhibitors (NRTIs) and ritonavir-boosted atazanavir (ATV/r) once daily or ritonavir-boosted darunavir (DRV/r) once daily or twice daily.\n  * Participants enrolled after the implementation of Amendment 9:\n\n    * Cohorts 2, 3 and 4 (Group 1): 2 NRTIs plus a third agent per local prescribing guidelines. Participants will switch from their current third agent to ATV or darunavir (DRV) at Day 1. Participants taking DRV must be on once-daily dosing or must switch to once daily at or prior to Day 1. Cohort 4 (Group 1), participants may also switch their current third agent to lopinavir boosted with ritonavir (LPV/r) at Day 1. Participants will switch their NRTI backbone to emtricitabine/tenofovir alafenamide (coformulated; Descovy\u00ae) (F/TAF).\n    * Cohort 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3): 2 NRTIs plus a third agent per local prescribing guidelines or treatment naive. Participants on treatment will switch from their current third agent to ATV or LPV/r (Cohort 4 (Groups 2 to 4)), or to a third unboosted agent (Cohort 5 (Groups 1 to 3)). Participants will switch their NRTI backbone to F/TAF.\n* Participants undergoing dose modifications to their ARV regimen for growth or switching medication formulations are considered to be on a stable ARV regimen.\n* Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) for \u2265 3 months preceding the screening visit:\n\n  * Participants enrolled after the implementation of Amendment 9:\n\n    * For Cohorts 2, 3, and 4 (Group 1), virologically suppressed \u2265 3 months preceding the screening visit: HIV-1 RNA \\< 50 copies/mL on a stable regimen (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is \u2265 50 copies/mL).\n    * For Cohorts 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3), on an ARV regimen irrespective of plasma HIV-1 RNA copies or treatment naive; a participant is considered treatment naive, if ARVs were given for prevention of mother-to-child transmission but not for HIV treatment.\n  * For virologically suppressed participants, unconfirmed virologic elevations of HIV-1 RNA \u2265 50 copies/mL (transient detectable viremia, or \"blip\") prior to screening are acceptable. If the lower limit of detection of the local HIV-1 RNA assay is \\< 50 copies/mL (eg, \\< 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50 copies/mL on 2 consecutive HIV-1 RNA tests.\n* Adequate renal function: Estimated glomerular filtration rate (eGFR) \u2265 90 mL/min/1.73m2 using the Schwartz formula. If \u2265 1 year old, eGFR greater than or equal to the minimum normal value for age using the Schwartz formula. If \\< 1 year old as follows:\n\n  * Age minimum value for eGFR (mL/min/1.73 m2) \\> 28 days to \u2264 95 days is 30, \u2265 96 days to \u2264 6 months is 39, \\> 6 to \\< 12 months is 49.\n* Participants must not have documented or suspected resistance to applicable study drugs including emtricitabine (Emtriva\u00ae) (FTC), TFV, ATV, DRV, or LPV. Participants \\< 14 kg (Cohorts 4 (Groups 2 to 4) and 5 (Groups 1 to 3)) with M184V/I AND HIV-1 RNA \\< 50 copies/mL will be allowed.\n* Positive confirmatory HIV test (confirmatory nucleic acid-based testing if \\< 18 months of age).\n* Cohort 4 (Groups 2 to 4) and Cohort 5 (Groups 1 to 3): Last dose of nevirapine or efavirenz, if applicable, \u2265 14 days prior to enrollment.\n\nNote: Other protocol defined Inclusion/Exclusion criteria do apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "4 Weeks",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Study Team",
                    "role": "CONTACT",
                    "email": "GSUS2160128@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Pediatric Infectious Disease Associates",
                    "status": "COMPLETED",
                    "city": "Long Beach",
                    "state": "California",
                    "zip": "90806",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.76696,
                        "lon": -118.18923
                    }
                },
                {
                    "facility": "Jeffrey Goodman Special Care Clinic",
                    "status": "WITHDRAWN",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90027",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Peter Morton Medical Building",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of Colorado Denver",
                    "status": "COMPLETED",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "The George Washington University",
                    "status": "COMPLETED",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "University of South Florida",
                    "status": "COMPLETED",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33606",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Emory-Children's Center- Ponce Family and Youth Clinic",
                    "status": "WITHDRAWN",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30308",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Boston University Medical Center",
                    "status": "WITHDRAWN",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02118",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "New York University School of Medicine",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SUNY Upstate Medical University",
                    "status": "WITHDRAWN",
                    "city": "Syracuse",
                    "state": "New York",
                    "zip": "13210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.04812,
                        "lon": -76.14742
                    }
                },
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "University of Texas Health Science Center of Houston",
                    "status": "COMPLETED",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Hospital General de Agudos Cosme Argerich",
                    "status": "COMPLETED",
                    "city": "Buenos Aires",
                    "zip": "1151",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Fundacion Huesped",
                    "status": "WITHDRAWN",
                    "city": "Buenos Aires",
                    "zip": "1202",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Helios Salud",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Buenos Aires",
                    "zip": "C1141 ACG",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Hospital Jose Maria Ramos Mejia",
                    "status": "WITHDRAWN",
                    "city": "Buenos Aires",
                    "zip": "C1221ADC",
                    "country": "Argentina",
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Hopital del Nino",
                    "status": "WITHDRAWN",
                    "city": "Panama City",
                    "zip": "0816-00383",
                    "country": "Panama",
                    "geoPoint": {
                        "lat": 8.9936,
                        "lon": -79.51973
                    }
                },
                {
                    "facility": "University of the Free State",
                    "status": "COMPLETED",
                    "city": "Bloemfontein",
                    "zip": "9300",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -29.12107,
                        "lon": 26.214
                    }
                },
                {
                    "facility": "University of Stellenbosch",
                    "status": "RECRUITING",
                    "city": "Cape Town",
                    "zip": "7505",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -33.92584,
                        "lon": 18.42322
                    }
                },
                {
                    "facility": "Dr. J. Fourie Medical Practice",
                    "status": "WITHDRAWN",
                    "city": "Dundee",
                    "zip": "3000",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -28.16678,
                        "lon": 30.23371
                    }
                },
                {
                    "facility": "King Edward VIII Hospital",
                    "status": "RECRUITING",
                    "city": "Durban",
                    "zip": "3629",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -29.8579,
                        "lon": 31.0292
                    }
                },
                {
                    "facility": "VIDA-Nkanyezi",
                    "status": "RECRUITING",
                    "city": "Johannesburg",
                    "zip": "2093",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -26.20227,
                        "lon": 28.04363
                    }
                },
                {
                    "facility": "Be Part Yoluntu Centre",
                    "status": "WITHDRAWN",
                    "city": "Paarl",
                    "zip": "7626",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -33.73378,
                        "lon": 18.97523
                    }
                },
                {
                    "facility": "The Aurum Institute: Pretoria Clinical Research Centre",
                    "status": "RECRUITING",
                    "city": "Pretoria",
                    "zip": "87",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -25.74486,
                        "lon": 28.18783
                    }
                },
                {
                    "facility": "Perinatal HIV Research Unit",
                    "status": "RECRUITING",
                    "city": "Soweto",
                    "zip": "2013",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -26.26781,
                        "lon": 27.85849
                    }
                },
                {
                    "facility": "HIV-NAT",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Bangkok",
                    "zip": "10330",
                    "country": "Thailand",
                    "geoPoint": {
                        "lat": 13.75398,
                        "lon": 100.50144
                    }
                },
                {
                    "facility": "Siriraj Hospital",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Bangkok",
                    "zip": "10700",
                    "country": "Thailand",
                    "geoPoint": {
                        "lat": 13.75398,
                        "lon": 100.50144
                    }
                },
                {
                    "facility": "Srinagarind Hospital",
                    "status": "COMPLETED",
                    "city": "Khon Kaen",
                    "zip": "40002",
                    "country": "Thailand",
                    "geoPoint": {
                        "lat": 16.44671,
                        "lon": 102.833
                    }
                },
                {
                    "facility": "Queen Savang Vadhana Memorial Hospital",
                    "status": "WITHDRAWN",
                    "city": "Sriracha",
                    "zip": "20110",
                    "country": "Thailand"
                },
                {
                    "facility": "MU-JHU Research Collaboration/MU-JHU Care Ltd",
                    "status": "RECRUITING",
                    "city": "Kampala",
                    "zip": "256",
                    "country": "Uganda",
                    "geoPoint": {
                        "lat": 0.31628,
                        "lon": 32.58219
                    }
                },
                {
                    "facility": "SICRA-TASO Mulago National Referral Hospital",
                    "status": "RECRUITING",
                    "city": "Kampala",
                    "country": "Uganda",
                    "geoPoint": {
                        "lat": 0.31628,
                        "lon": 32.58219
                    }
                },
                {
                    "facility": "AMBSO Masaka Clinical Research Site",
                    "status": "RECRUITING",
                    "city": "Masaka",
                    "country": "Uganda",
                    "geoPoint": {
                        "lat": -0.33379,
                        "lon": 31.73409
                    }
                },
                {
                    "facility": "Imperial College Healthcare NHS Trust",
                    "status": "COMPLETED",
                    "city": "London",
                    "zip": "W2 1NY",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "University of Zimbabwe Clinical Research Centre",
                    "status": "RECRUITING",
                    "city": "Harare",
                    "country": "Zimbabwe",
                    "geoPoint": {
                        "lat": -17.82772,
                        "lon": 31.05337
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study/?id=GS-US-216-0128"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015658",
                    "term": "HIV Infections"
                },
                {
                    "id": "D000000163",
                    "term": "Acquired Immunodeficiency Syndrome"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                }
            ],
            "ancestors": [
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000015229",
                    "term": "Sexually Transmitted Diseases, Viral"
                },
                {
                    "id": "D000012749",
                    "term": "Sexually Transmitted Diseases"
                },
                {
                    "id": "D000016180",
                    "term": "Lentivirus Infections"
                },
                {
                    "id": "D000012192",
                    "term": "Retroviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000012897",
                    "term": "Slow Virus Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "asFound": "Acquired Immune Deficiency Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "asFound": "Acquired Immune Deficiency Syndrome (AIDS)",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "asFound": "Immune Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15558",
                    "name": "Sexually Transmitted Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17933",
                    "name": "Sexually Transmitted Diseases, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M18640",
                    "name": "Lentivirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15026",
                    "name": "Retroviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15700",
                    "name": "Slow Virus Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069547",
                    "term": "Cobicistat"
                },
                {
                    "id": "C000613801",
                    "term": "Emtricitabine tenofovir alafenamide"
                },
                {
                    "id": "D000068679",
                    "term": "Emtricitabine"
                },
                {
                    "id": "D000068698",
                    "term": "Tenofovir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000065692",
                    "term": "Cytochrome P-450 CYP3A Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000018894",
                    "term": "Reverse Transcriptase Inhibitors"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M21243",
                    "name": "Lamivudine",
                    "relevance": "LOW"
                },
                {
                    "id": "M295",
                    "name": "Rilpivirine",
                    "relevance": "LOW"
                },
                {
                    "id": "M296",
                    "name": "Tenofovir",
                    "asFound": "Transoral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M294",
                    "name": "Emtricitabine",
                    "asFound": "Transoral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1852",
                    "name": "Maraviroc",
                    "relevance": "LOW"
                },
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M347662",
                    "name": "Dolutegravir",
                    "relevance": "LOW"
                },
                {
                    "id": "M21394",
                    "name": "Ritonavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M350770",
                    "name": "Abacavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M459",
                    "name": "Cobicistat",
                    "asFound": "Discontinue",
                    "relevance": "HIGH"
                },
                {
                    "id": "M343325",
                    "name": "Emtricitabine tenofovir alafenamide",
                    "asFound": "Transoral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M423",
                    "name": "Darunavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M29837",
                    "name": "Lopinavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M20935",
                    "name": "Reverse Transcriptase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M340137",
                    "name": "Efavirenz",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M333",
                    "name": "Raltegravir Potassium",
                    "relevance": "LOW"
                },
                {
                    "id": "M415",
                    "name": "Atazanavir Sulfate",
                    "relevance": "LOW"
                },
                {
                    "id": "M21770",
                    "name": "Nelfinavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M17920",
                    "name": "Zidovudine",
                    "relevance": "LOW"
                },
                {
                    "id": "M339955",
                    "name": "Etravirine",
                    "relevance": "LOW"
                },
                {
                    "id": "M292744",
                    "name": "Elvitegravir",
                    "relevance": "LOW"
                },
                {
                    "id": "M21717",
                    "name": "Nevirapine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20272",
                    "name": "Stavudine",
                    "relevance": "LOW"
                },
                {
                    "id": "M21424",
                    "name": "Indinavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M21242",
                    "name": "Saquinavir",
                    "relevance": "LOW"
                },
                {
                    "id": "M21867",
                    "name": "Delavirdine",
                    "relevance": "LOW"
                },
                {
                    "id": "M18548",
                    "name": "Didanosine",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M30564",
                    "name": "Cytochrome P-450 CYP3A Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}